@article{BrunkhorstKanaanTrautmannSchreiberetal.2021,
  author    = {Brunkhorst-Kanaan, Nathalie and Trautmann, Sandra and Schreiber, Yannick and Thomas, Dominique and Kittel-Schneider, Sarah and Gurke, Robert and Geisslinger, Gerd and Reif, Andreas and Tegeder, Irmgard},
  title     = {Sphingolipid and endocannabinoid profiles in adult attention deficit hyperactivity disorder},
  series = {Biomedicines},
  volume    = {9},
  journal   = {Biomedicines},
  number    = {9},
  issn      = {2227-9059},
  doi       = {10.3390/biomedicines9091173},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-246080},
  year      = {2021},
  abstract  = {Genes encoding endocannabinoid and sphingolipid metabolism pathways were suggested to contribute to the genetic risk towards attention deficit hyperactivity disorder (ADHD). The present pilot study assessed plasma concentrations of candidate endocannabinoids, sphingolipids and ceramides in individuals with adult ADHD in comparison with healthy controls and patients with affective disorders. Targeted lipid analyses of 23 different lipid species were performed in 71 mental disorder patients and 98 healthy controls (HC). The patients were diagnosed with adult ADHD (n = 12), affective disorder (major depression, MD n = 16 or bipolar disorder, BD n = 6) or adult ADHD with comorbid affective disorders (n = 37). Canonical discriminant analysis and CHAID analyses were used to identify major components that predicted the diagnostic group. ADHD patients had increased plasma concentrations of sphingosine-1-phosphate (S1P d18:1) and sphinganine-1-phosphate (S1P d18:0). In addition, the endocannabinoids, anandamide (AEA) and arachidonoylglycerol were increased. MD/BD patients had increased long chain ceramides, most prominently Cer22:0, but low endocannabinoids in contrast to ADHD patients. Patients with ADHD and comorbid affective disorders displayed increased S1P d18:1 and increased Cer22:0, but the individual lipid levels were lower than in the non-comorbid disorders. Sphingolipid profiles differ between patients suffering from ADHD and affective disorders, with overlapping patterns in comorbid patients. The S1P d18:1 to Cer22:0 ratio may constitute a diagnostic or prognostic tool.},
  language  = {en}
}
@article{WieseDennstaedtHollmannetal.2021,
  author    = {Wiese, Teresa and Dennst{\"a}dt, Fabio and Hollmann, Claudia and Stonawski, Saskia and Wurst, Catherina and Fink, Julian and Gorte, Erika and Mandasari, Putri and Domschke, Katharina and Hommers, Leif and Vanhove, Bernard and Schumacher, Fabian and Kleuser, Burkard and Seibel, J{\"u}rgen and Rohr, Jan and Buttmann, Mathias and Menke, Andreas and Schneider-Schaulies, J{\"u}rgen and Beyersdorf, Niklas},
  title     = {Inhibition of acid sphingomyelinase increases regulatory T cells in humans},
  series = {Brain Communications},
  volume    = {3},
  journal   = {Brain Communications},
  number    = {2},
  doi       = {10.1093/braincomms/fcab020},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-259868},
  year      = {2021},
  abstract  = {Genetic deficiency for acid sphingomyelinase or its pharmacological inhibition has been shown to increase Foxp3\(^+\) regulatory T-cell frequencies among CD4\(^+\) T cells in mice. We now investigated whether pharmacological targeting of the acid sphingomyelinase, which catalyzes the cleavage of sphingomyelin to ceramide and phosphorylcholine, also allows to manipulate relative CD4\(^+\) Foxp3\(^+\) regulatory T-cell frequencies in humans. Pharmacological acid sphingomyelinase inhibition with antidepressants like sertraline, but not those without an inhibitory effect on acid sphingomyelinase activity like citalopram, increased the frequency of Foxp3\(^+\) regulatory T cell among human CD4\(^+\) T cells in vitro. In an observational prospective clinical study with patients suffering from major depression, we observed that acid sphingomyelinase-inhibiting antidepressants induced a stronger relative increase in the frequency of CD4\(^+\) Foxp3\(^+\) regulatory T cells in peripheral blood than acid sphingomyelinase-non- or weakly inhibiting antidepressants. This was particularly true for CD45RA\(^-\) CD25\(^{high}\) effector CD4\(^+\) Foxp3\(^+\) regulatory T cells. Mechanistically, our data indicate that the positive effect of acid sphingomyelinase inhibition on CD4\(^+\) Foxp3\(^+\) regulatory T cells required CD28 co-stimulation, suggesting that enhanced CD28 co-stimulation was the driver of the observed increase in the frequency of Foxp3+ regulatory T cells among human CD4\(^+\) T cells. In summary, the widely induced pharmacological inhibition of acid sphingomyelinase activity in patients leads to an increase in Foxp3+ regulatory T-cell frequencies among CD4\(^+\) T cells in humans both in vivo and in vitro.},
  language  = {en}
}
@article{ZapfFinze2021,
  author    = {Zapf, Ludwig and Finze, Maik},
  title     = {The crystal structure of poly[(μ \(_3\)-imidazolato-κ \(^3\) N:N:N′)(tetrahydrofuran- κ \(^1\) O)lithium(I)], C\(_7\)H\(_{11}\)LiN\(_2\)O},
  series = {Zeitschrift f{\"u}r Kristallographie - New Crystal Structures},
  volume    = {236},
  journal   = {Zeitschrift f{\"u}r Kristallographie - New Crystal Structures},
  number    = {5},
  doi       = {10.1515/ncrs-2021-0192},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-260745},
  pages     = {1007-1009},
  year      = {2021},
  abstract  = {C\(_7\)H\(_{11}\)LiN\(_2\)O, monoclinic, P2\(_1\)/c (no. 14), a = 8.9067(1) angstrom, b = 8.6975(1) angstrom, c = 10.2398(1) angstrom, beta = 101.900(3)degrees, V = 770.491(15) angstrom(3), Z = 4, R-gt (F) = 0.0338, wR(ref) (F\(^2\)) = 0.0925, T = 100 K.},
  language  = {en}
}